Chronic migraine is defined as headache occurring 15 or more days per month for more than 3 months, with at least 8 of those days meeting criteria for migraine. It affects approximately 2% of the global population and is associated with profoundly disabling light sensitivity — often persistent even between attacks, not just during them.

Photophobia in Chronic vs. Episodic Migraine

In episodic migraine, photophobia occurs during attacks and typically resolves completely in the interictal (between-attack) period. In chronic migraine, this boundary blurs:

Interictal photophobia is present in up to 60% of chronic migraine patients — meaning light sensitivity persists even on headache-free days
The severity of interictal photophobia correlates with attack frequency; the more days with headache per month, the worse the baseline light sensitivity
Chronic migraine patients often report that they must permanently modify their environment (dimmer lights, sunglasses indoors, screen filters) rather than only during attacks

This persistent photophobia reflects underlying central sensitization — a state of amplified pain processing in the central nervous system that becomes entrenched in chronic migraine.

Central Sensitization: The Core Mechanism

Central sensitization is the neurological process that drives both the transformation from episodic to chronic migraine and the persistent photophobia:

Allodynia. Up to 80% of chronic migraine patients develop allodynia — pain from normally non-painful stimuli. Light, which is normally non-painful, becomes consistently painful through sensitized thalamo-cortical circuits.

Cortical spreading depression (CSD) and visual cortex excitability. The migraine brain has a hyperexcitable visual cortex at baseline. In chronic migraine, this hyperexcitability is more pronounced and less likely to normalize between attacks.

Thalamic sensitization. The posterior thalamus (which relays visual signals) becomes sensitized in chronic migraine. Single-unit recordings in animal models show thalamic neurons that fire in response to light at intensities that are ordinarily subthreshold.

Medication Overuse Headache (MOH)

A critical but often overlooked factor in chronic migraine is medication overuse headache (MOH). Using acute headache medications (triptans, NSAIDs, opioids, ergotamines) more than 10–15 days per month paradoxically worsens headache frequency and chronification — and worsens photophobia.

MOH is present in approximately 50% of chronic migraine patients. Identifying and withdrawing overused medications (under medical supervision) is often the most impactful intervention for both headache frequency and light sensitivity.

Treatment

Preventive therapies are essential for chronic migraine — the goal is to reduce attack frequency below the chronic threshold:

CGRP monoclonal antibodies (erenumab/Aimovig, fremanezumab/Ajovy, galcanezumab/Emgality) — first-line preventive; directly target the CGRP pathway driving sensitization and photophobia
OnabotulinumtoxinA (Botox) — FDA-approved specifically for chronic migraine; 31-injection protocol every 12 weeks
Topiramate, valproate, amitriptyline, propranolol — traditional preventives
Gepants (rimegepant/Nurtec, atogepant/Qulipta) — newer oral CGRP receptor antagonists with both acute and preventive efficacy

Managing persistent interictal photophobia:

FL-41 tinted lenses — reduce interictal photophobia and may reduce attack frequency by limiting photic triggers; worn as daily-use glasses
Screen filters (blue light blocking overlays), f.lux or Night Shift on devices
Workplace accommodations: reduced overhead fluorescent lighting, task lighting, glare-free monitors
Sunglasses habituation: while protective outdoors, wearing dark glasses indoors can worsen photosensitivity by dark-adapting the visual system; FL-41 is a better indoor option

Lifestyle foundations:

Sleep regularity (go to bed and wake at same time daily)
Hydration (dehydration is a major trigger)
Stress management
Regular low-intensity aerobic exercise

Prognosis

With appropriate preventive treatment, many chronic migraine patients can revert to episodic migraine (fewer than 15 headache days/month). Photophobia typically improves proportionally with headache frequency reduction. CGRP antibodies have shown reduction in photophobia as a specific outcome measure in clinical trials.

Sources

Lipton RB, et al. “Prevalence and burden of migraine in the United States.” Neurology. 2007;68(5):343-349.
Aurora SK, Wilkinson F. “The brain is hyperexcitable in migraine.” Cephalalgia. 2007;27(12):1442-1453.
Schwedt TJ. “Chronic migraine.” BMJ. 2014;348:g1416.
Digre KB, Brennan KC. “Shedding light on photophobia.” J Neuro-Ophthalmol. 2012;32(1):68-81.

Chronic migraine light sensitivity: Causes, Symptoms & Management